Trending Topic

Brain head human mental idea mind 3D illustration background
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Cognitive impairment is the hallmark symptom of Alzheimer’s disease (AD); however, neuropsychiatric symptoms (NPS), including psychosis, agitation and mood disturbances, are common not only in AD but also in Parkinson’s disease, dementia with Lewy bodies, frontotemporal dementia and vascular dementia.1–5 Psychotic symptoms have been reported to be present in 12–74% of patients with AD, with […]

Sean Pittock, ECTRIMS 2022: Subgroup analyses from the phase 3 CHAMPION-NMOSD investigating ravulizumab for neuromyelitis optica spectrum disorder

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 9th 2022

The CHAMPION-NMOSD trial (NCT04201262) is a global, open-label, multicentre, phase 3, externally controlled study of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD). In this touchNEUROLOGY interview, we caught up with Prof. Sean Pittock (Mayo Clinic, Rochester, MN, USA) to discuss the pre-specified efficacy analyses in clinically relevant patient subgroups, and the effect ravulizumab may have on clinical practice if approved. Prof. Pittock also discusses the current treatment options available, and the challenges that arise in cost, access and diagnosis, such as the role that biomarkers play in diagnosing NMOSD globally.

The abstract entitled ‘Efficacy subgroup analyses from the phase 3 CHAMPION-NMOSD trial in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder’ (Abstract #P010) was presented at ECTRIMS, 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 26 – 28 October 2022, Amsterdam, the Netherlands.

Access a discussion by Prof. Sean Pittock on the full phase 3 CHAMPION-NMOSD trial results

Questions:

  1. What subgroup analyses were prespecified in the CHAMPION-NMOSD study? (0:30)
  2. What unanswered questions remain and what future studies are planned? (2:03)
  3. If approved, what will be the impact of ravulizumab on clinical practice? (4:47)

Disclosures: Prof. Sean Pittcock is a consultant for, and receives personal compensation from Roche/Genentech, UCB, Arialys Therapeutics, Sage Therapeutics; is a consultant for and receives compensation to the Mayo Clinic from Alexion, MedImmune/Viela Bio, and Astellas; receives grant/research Support from Alexion, MedImmue/Viela Bio/Horizon, Grifols, NovelMed, Genentech/Roche, and NIH; is on the advisory board for, and receives compensation to the Mayo Clinic from Alexion, Roche/Genentech; and is on the advisory board for and receives personal compensation from UCB, and Horizon Therapeutics.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of ECTRIMS 2022

Access more content on NMOSD here

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup